These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2196 related articles for article (PubMed ID: 26699864)
21. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing. Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617 [TBL] [Abstract][Full Text] [Related]
22. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations. Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430 [TBL] [Abstract][Full Text] [Related]
23. Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas. Siegal T Adv Tech Stand Neurosurg; 2016; (43):91-108. PubMed ID: 26508407 [TBL] [Abstract][Full Text] [Related]
24. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma. Karsy M; Guan J; Huang LE J Neurosurg; 2019 Jan; 130(1):56-66. PubMed ID: 29547090 [TBL] [Abstract][Full Text] [Related]
25. ATRX immunostaining predicts IDH and H3F3A status in gliomas. Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324 [TBL] [Abstract][Full Text] [Related]
26. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Liu XY; Gerges N; Korshunov A; Sabha N; Khuong-Quang DA; Fontebasso AM; Fleming A; Hadjadj D; Schwartzentruber J; Majewski J; Dong Z; Siegel P; Albrecht S; Croul S; Jones DT; Kool M; Tonjes M; Reifenberger G; Faury D; Zadeh G; Pfister S; Jabado N Acta Neuropathol; 2012 Nov; 124(5):615-25. PubMed ID: 22886134 [TBL] [Abstract][Full Text] [Related]
27. Chromosome 17p Homodisomy Is Associated With Better Outcome in 1p19q Non-Codeleted and IDH-Mutated Gliomas. Labussière M; Rahimian A; Giry M; Boisselier B; Schmitt Y; Polivka M; Mokhtari K; Delattre JY; Idbaih A; Labreche K; Alentorn A; Sanson M Oncologist; 2016 Sep; 21(9):1131-5. PubMed ID: 27401888 [TBL] [Abstract][Full Text] [Related]
28. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337 [TBL] [Abstract][Full Text] [Related]
29. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas. Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377 [TBL] [Abstract][Full Text] [Related]
30. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases. Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262 [TBL] [Abstract][Full Text] [Related]
31. Glioma biology and molecular markers. Cohen AL; Colman H Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223 [TBL] [Abstract][Full Text] [Related]
32. PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas. Nakae S; Sasaki H; Hayashi S; Hattori N; Kumon M; Nishiyama Y; Adachi K; Nagahisa S; Hayashi T; Inamasu J; Abe M; Hasegawa M; Hirose Y PLoS One; 2015; 10(11):e0142750. PubMed ID: 26558387 [TBL] [Abstract][Full Text] [Related]
38. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome. Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345 [TBL] [Abstract][Full Text] [Related]
39. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting. Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044 [TBL] [Abstract][Full Text] [Related]
40. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. Karsy M; Guan J; Cohen AL; Jensen RL; Colman H Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]